{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:15:46Z","timestamp":1786749346255,"version":"build-2736575974"},"reference-count":150,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100001137","name":"Australia Awards Ph.D. scholarship","doi-asserted-by":"publisher","award":["ST0009TM3"],"award-info":[{"award-number":["ST0009TM3"]}],"id":[{"id":"10.13039\/501100001137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2019,4,24]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to\ncastration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as\np53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing\nof metformin (MET) and valproic acid (VPA) either when used alone, or in combination,\nwith another therapy, could potentially play a role in slowing down PCa progression. This review\nprovides an overview of the application of MET and VPA, both alone and in combination with other\ndrugs for PCa treatment, correlates the responses to these drugs with common molecular changes in\nPCa, and then describes the potential for combined MET and VPA as a systemic therapy for prostate\ncancer, based on potential interacting mechanisms.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009618666180724111604","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T10:43:24Z","timestamp":1532429004000},"page":"368-381","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination Therapies Using Metformin and\/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions"],"prefix":"10.2174","volume":"19","author":[{"given":"Linh N.K.","family":"Tran","sequence":"first","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Sykes","sequence":"additional","affiliation":[{"name":"Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","volume":"361","author":"Gr\u00f6nberg H.","year":"2003","unstructured":"Gr\u00f6nberg H. Lancet, Prostate cancer epidemiology., 2003, 361, 859-864,","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"Torre L.A.","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet\u2010Tieulent J, Jemal A. CA Cancer J Clin, Global cancer statistics, 2012., 2015, 65, 87-108,","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"Heidenreich A.","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F. Eur Urol, EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013., 2014, 65, 124-137,","journal-title":"Eur Urol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.canep.2015.04.013","volume":"39","author":"Luo Q.","year":"2015","unstructured":"Luo Q, Yu XQ, Smith DP, O\u2019Connell DL. Cancer Epidemiol, A population-based study of progression to metastatic prostate cancer in Australia., 2015, 39, 617-622,","journal-title":"Cancer Epidemiol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.canep.2012.07.012","volume":"36","author":"Hirst C.","year":"2012","unstructured":"Hirst C, Cabrera C, Kirby M. Cancer Epidemiol, Epidemiology of castration resistant prostate cancer: A longitudinal analysis using a UK primary care database., 2012, 36, e349-e353,","journal-title":"Cancer Epidemiol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"Ryan C.J.","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ. Lancet Oncol, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study., 2015, 16, 152-160,","journal-title":"Lancet Oncol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"Beer T.M.","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S. N Engl J Med, Enzalutamide in metastatic prostate cancer before chemotherapy., 2014, 371, 424-433,","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"Tannock I.F.","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I. N Engl J Med, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer., 2004, 351, 1502-1512,","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"Kantoff P.W.","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB. N Engl J Med, Sipuleucel-T immunotherapy for castration-resistant prostate cancer., 2010, 363, 411-422,","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"De Bono J.S.","year":"2010","unstructured":"De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L. Lancet, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial., 2010, 376, 1147-1154,","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"Nilsson S.","year":"2007","unstructured":"Nilsson S, Franz\u00e9n L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennern\u00e4s B, Petersson U, Johannessen DC, Sokal M. Lancet Oncol, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study., 2007, 8, 587-594,","journal-title":"Lancet Oncol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF01862957","volume":"125","author":"M\u00fcller H.","year":"1927","unstructured":"M\u00fcller H, Reinwein H. Pathol Pharmakol, Zur Pharmakologie des Galegins. Naunyn-Schmiedebergs Archiv experiment., 1927, 125, 212-228,","journal-title":"Pathol Pharmakol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1120781","volume":"310","author":"Shaw R.J.","year":"2005","unstructured":"Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA, Montminy M, Cantley LC. Science, The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin., 2005, 310, 1642-1646,","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF00401836","volume":"38","author":"Kozka I.","year":"1995","unstructured":"Kozka I, Clark A, Reckless J, Cushman S, Gould G, Holman G. Diabetologia, The effects of insulin on the level and activity of the GLUT4 present in human adipose cells., 1995, 38, 661-666,","journal-title":"Diabetologia"},{"key":"ref=15","first-page":"385","volume":"3","author":"Burton B.","year":"1882","unstructured":"Burton B. J Am Chem Soc, On the propyl derivatives and decomposition products of ethylacetoacetate., 1882, 3, 385-395,","journal-title":"J Am Chem Soc"},{"key":"ref=16","first-page":"435","volume":"18","author":"Meunier H.","year":"1962","unstructured":"Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M. Therapie, Pharmacodynamic properties of N-dipropylacetic acid., 1962, 18, 435-438,","journal-title":"Therapie"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/j.1582-4934.2008.00471.x","volume":"13","author":"Chen Y.","year":"2009","unstructured":"Chen Y, Pan RL, Zhang XL, Shao JZ, Xiang LX, Dong XJ, Zhang GR. J Cell Mol Med, Induction of hepatic differentiation of mouse bone marrow stromal stem cells by the histone deacetylase inhibitor VPA., 2009, 13, 2582-2592,","journal-title":"J Cell Mol Med"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"Zhou G.","year":"2001","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N. J Clin Invest, Role of AMP-activated protein kinase in mechanism of metformin action., 2001, 108, 1167-1174,","journal-title":"J Clin Invest"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","volume":"27","author":"Ben-Sahra I.","year":"2008","unstructured":"Ben-Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti J-F, Le Marchand-Brustel Y, Bost F. Oncogene, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level., 2008, 27, 3576-3586,","journal-title":"Oncogene"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"23977","DOI":"10.1074\/jbc.C200171200","volume":"277","author":"Bolster D.R.","year":"2002","unstructured":"Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. J Biol Chem, AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling., 2002, 277, 23977-23980,","journal-title":"J Biol Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI29044","volume":"116","author":"Long Y.C.","year":"2006","unstructured":"Long YC, Zierath JR. J Clin Invest, AMP-activated protein kinase signaling in metabolic regulation., 2006, 116, 1776-1783,","journal-title":"J Clin Invest"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","volume":"19","author":"Bradbury C.","year":"2005","unstructured":"Bradbury C, Khanim F, Hayden R, Bunce C, White D, Drayson M, Craddock C, Turner B. Leukemia, Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors., 2005, 19, 1751-1759,","journal-title":"Leukemia"},{"key":"ref=23","first-page":"3637","volume":"63","author":"Rosato R.R.","year":"2003","unstructured":"Rosato RR, Almenara JA, Grant S. Cancer Res, The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1., 2003, 63, 3637-3645,","journal-title":"Cancer Res"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2006.08.010","volume":"549","author":"Savickiene J.","year":"2006","unstructured":"Savickiene J, Borutinskaite V-V, Treigyte G, Magnusson K-E, Navakauskiene R. Eur J Pharmacol, The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines., 2006, 549, 9-18,","journal-title":"Eur J Pharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1124\/jpet.105.096891","volume":"317","author":"Martirosyan A.","year":"2006","unstructured":"Martirosyan A, Leonard S, Shi X, Griffith B, Gannett P, Strobl J. J Pharmacol Exp Ther, Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells., 2006, 317, 546-552,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","volume":"66","author":"Rothermundt C.","year":"2014","unstructured":"Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, B\u00e4rtschi D, Pollak M, Lui L, Endt K, Schiess R. Eur Urol, Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)., 2014, 66, 468-474,","journal-title":"Eur Urol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/1055-9965.EPI-10-0940","volume":"20","author":"Azoulay L.","year":"2011","unstructured":"Azoulay L, Dell\u2019Aniello S, Gagnon B, Pollak M, Suissa S. Cancer Epidemiol Biomarkers Prev, Metformin and the incidence of prostate cancer in patients with type 2 diabetes., 2011, 20, 337-344,","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/pcan.2015.8","volume":"18","author":"Joerger M.","year":"2015","unstructured":"Joerger M, van Schaik R, Becker M, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. Prostate Cancer Prostatic Dis, Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08\/09)., 2015, 18, 167-172,","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/0008-5472.CAN-13-0080","volume":"73","author":"Fendt S-M.","year":"2013","unstructured":"Fendt S-M, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A. Cancer Res, Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism., 2013, 73, 4429-4438,","journal-title":"Cancer Res"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","volume":"71","author":"Ben-Sahra I.","year":"2011","unstructured":"Ben-Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti J-F, Giorgetti-Peraldi S, Bost F. Cancer Res, Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1., 2011, 71, 4366-4372,","journal-title":"Cancer Res"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/15563650.2013.860985","volume":"52","author":"Vecchio S.","year":"2014","unstructured":"Vecchio S, Giampreti A, Petrolini V, Lonati D, Protti A, Papa P, Rognoni C, Valli A, Rocchi L, Rolandi L. Clin Toxicol, Metformin accumulation: Lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy., 2014, 52, 129-135,","journal-title":"Clin Toxicol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-12-0007","volume":"48","author":"Dowling R.J.","year":"2012","unstructured":"Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. J Mol Endocrinol, Metformin in cancer: translational challenges., 2012, 48, R31-R43,","journal-title":"J Mol Endocrinol"},{"key":"ref=33","first-page":"3047","volume":"7","author":"Carducci M.A.","year":"2001","unstructured":"Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen T-I, Grochow LB, Donehower RC. Clin Cancer Res, A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule., 2001, 7, 3047-3055,","journal-title":"Clin Cancer Res"},{"key":"ref=34","first-page":"718","volume":"8","author":"Sandor V.","year":"2002","unstructured":"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD. Clin Cancer Res, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms., 2002, 8, 718-728,","journal-title":"Clin Cancer Res"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"Kelly W.K.","year":"2005","unstructured":"Kelly WK, O\u2019connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L. J Clin Oncol, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer., 2005, 23, 3923-3931,","journal-title":"J Clin Oncol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","volume":"67","author":"Shabbeer S.","year":"2007","unstructured":"Shabbeer S, Kortenhorst MSQ, Kachhap S, Galloway N, Rodriguez R, Carducci MA. Prostate, Multiple molecular pathways explain the anti\u2010proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo., 2007, 67, 1099-1110,","journal-title":"Prostate"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"180363","DOI":"10.1155\/2012\/180363","volume":"2012","author":"Sidana A.","year":"2012","unstructured":"Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. J Biomed Biotechnol, Mechanism of growth inhibition of prostate cancer xenografts by valproic acid., 2012, 2012, 180363-,","journal-title":"J Biomed Biotechnol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","volume":"29","author":"Yang H.","year":"2005","unstructured":"Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Leuk Res, Antileukemia activity of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid., 2005, 29, 739-748,","journal-title":"Leuk Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","volume":"97","author":"Atmaca A.","year":"2007","unstructured":"Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, Jager E. Br J Cancer, Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial., 2007, 97, 177-182,","journal-title":"Br J Cancer"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1179\/joc.2006.18.4.415","volume":"18","author":"Friedmann I.","year":"2006","unstructured":"Friedmann I, Atmaca A, Chow KU, Jager E, Weidmann E. J Chemother, Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer., 2006, 18, 415-420,","journal-title":"J Chemother"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1593\/tlo.08136","volume":"1","author":"Sharma S.","year":"2008","unstructured":"Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N. Transl Oncol, A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy., 2008, 1, 141-,","journal-title":"Transl Oncol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","volume":"16","author":"Mahalingam D.","year":"2010","unstructured":"Mahalingam D, Medina EC, Esquivel JA, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC. Clin Cancer Res, Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels., 2010, 16, 141-153,","journal-title":"Clin Cancer Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"Vogelstein B.","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Science, Cancer genome landscapes., 2013, 339, 1546-1558,","journal-title":"Science"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"2012","author":"Gerlinger M.","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P. N Engl J Med, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing., 2012, 2012, 883-892,","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2159-8290.CD-14-1118","volume":"5","author":"Dienstmann R.","year":"2015","unstructured":"Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Cancer Discov, Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors., 2015, 5, 118-123,","journal-title":"Cancer Discov"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-004-0473-1","volume":"23","author":"So A.","year":"2005","unstructured":"So A, Gleave M, Hurtado-Col A, Nelson C. World J Urol, Mechanisms of the development of androgen independence in prostate cancer., 2005, 23, 1-9,","journal-title":"World J Urol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"Gravis G.","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B. Lancet Oncol, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial., 2013, 14, 149-158,","journal-title":"Lancet Oncol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"James N.D.","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G. Lancet, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial., 2016, 387, 1163-1177,","journal-title":"Lancet"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/pcan.2012.16","volume":"15","author":"Colquhoun A.","year":"2012","unstructured":"Colquhoun A, Venier N, Vandersluis A, Besla R, Sugar L, Kiss A, Fleshner N, Pollak M, Klotz L, Venkateswaran V. Prostate Cancer Prostatic Dis, Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer., 2012, 15, 346-352,","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/pros.23000","volume":"75","author":"Wang Y.","year":"2015","unstructured":"Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J. Prostate, Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor., 2015, 75, 1187-1196,","journal-title":"Prostate"},{"key":"ref=51","first-page":"1004","volume":"1","author":"Chen-Pin W.","year":"2014","unstructured":"Chen-Pin W, Javier H, Lorenzo C, Downs JR, Thompson IM, Pollock B, Lehman D. Ann Transl Med Epidemiol, Statins and finasteride use differentially modify the impact of metformin on prostate cancer incidence in men with type 2 diabetes., 2014, 1, 1004-,","journal-title":"Ann Transl Med Epidemiol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"Warburg O.","year":"1956","unstructured":"Warburg O. Science, On the origin of cancer cells., 1956, 123, 309-314,","journal-title":"Science"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-09-2782","volume":"70","author":"Ben-Sahra I.","year":"2010","unstructured":"Ben-Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C. Cancer Res, Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells., 2010, 70, 2465-2475,","journal-title":"Cancer Res"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2337\/dc11-1829","volume":"35","author":"Lehman D.M.","year":"2012","unstructured":"Lehman DM, Lorenzo C, Hernandez J, Wang CP. Diabetes Care, Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients., 2012, 35, 1002-1007,","journal-title":"Diabetes Care"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/pcan.2014.47","volume":"18","author":"Danzig M.R.","year":"2015","unstructured":"Danzig MR, Kotamarti S, Ghandour RA, Rothberg MB, Dubow BP, Benson MC, Badani KK, McKiernan JM. Prostate Cancer Prostatic Dis, Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes., 2015, 18, 63-68,","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-14-0451","volume":"13","author":"Babcook M.A.","year":"2014","unstructured":"Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, Oak CZ, MacLennan GT, Flask CA, Lindner DJ. Mol Cancer Ther, Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer., 2014, 13, 2288-2302,","journal-title":"Mol Cancer Ther"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2016.06.036","volume":"788","author":"Pennanen P.","year":"2016","unstructured":"Pennanen P, Syvala H, Blauer M, Savinainen K, Ylikomi T, Tammela TL, Murtola TJ. Eur J Pharmacol, The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines., 2016, 788, 160-167,","journal-title":"Eur J Pharmacol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1940-6207.CAPR-15-0014","volume":"8","author":"Saha A.","year":"2015","unstructured":"Saha A, Blando J, Tremmel L, DiGiovanni J. Cancer Prev Res, Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice., 2015, 8, 597-606,","journal-title":"Cancer Prev Res"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1210\/jc.2015-3555","volume":"101","author":"Al-Hendy A.","year":"2016","unstructured":"Al-Hendy A, Diamond MP, Boyer TG, Halder SK. J Clin Endocrinol Metab, Vitamin D3 inhibits Wnt\/\u03b2-catenin and mTOR signaling pathways in human uterine fibroid cells., 2016, 101, 1542-1551,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1440-1681.12409","volume":"42","author":"Li H.X.","year":"2015","unstructured":"Li HX, Gao JM, Liang JQ, Xi JM, Fu M, Wu YJ. Clin Exp Pharmacol Physiol, Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK\/mTOR signalling pathway., 2015, 42, 711-717,","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00001813-199609000-00008","volume":"7","author":"Cinatl J.","year":"1996","unstructured":"Cinatl J, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel J-U, Doerr HW, Kornhuber B. Anticancer Drugs, Antitumor activity of sodium valproate in cultures of human neuroblastoma cells., 1996, 7, 766-773,","journal-title":"Anticancer Drugs"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.jprot.2011.06.016","volume":"74","author":"Ouyang D-Y.","year":"2011","unstructured":"Ouyang D-Y, Ji Y-H, Saltis M, Xu L-H, Zhang Y-T, Zha Q-B, Cai J-Y, He X-H. J Proteomics, Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis., 2011, 74, 2180-2193,","journal-title":"J Proteomics"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1096\/fj.12-222893","volume":"27","author":"Wissing M.D.","year":"2013","unstructured":"Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E, Hammers H, van Diest PJ, Carducci MA, Kachhap SK. FASEB J, Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors., 2013, 27, 4279-4293,","journal-title":"FASEB J"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/cam4.289","volume":"3","author":"Paller C.J.","year":"2014","unstructured":"Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK. Cancer Med, Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer., 2014, 3, 1322-1335,","journal-title":"Cancer Med"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-04-0540","volume":"64","author":"Qian D.Z.","year":"2004","unstructured":"Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. Cancer Res, The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787\/ZK222584., 2004, 64, 6626-6634,","journal-title":"Cancer Res"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00280-014-2384-1","volume":"73","author":"Wheler J.J.","year":"2014","unstructured":"Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Cancer Chemother Pharmacol, Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers., 2014, 73, 495-501,","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pros.21288","volume":"71","author":"Wedel S.","year":"2011","unstructured":"Wedel S, Hudak L, Seibel JM, Juengel E, Oppermann E, Haferkamp A, Blaheta RA. The Prostate, Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer., 2011, 71, 722-735,","journal-title":"The Prostate"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1128\/MCB.00605-06","volume":"26","author":"Annicotte J.S.","year":"2006","unstructured":"Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noel D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S, Fajas L. Mol Cell Biol, Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer., 2006, 26, 7561-7574,","journal-title":"Mol Cell Biol"},{"key":"ref=69","first-page":"111","volume":"39","author":"Fortson W.S.","year":"2011","unstructured":"Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE, Rao VN, Bhat GK, Reddy ESP. Int J Oncol, Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells., 2011, 39, 111-,","journal-title":"Int J Oncol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4161\/cbt.9.9.11436","volume":"9","author":"David K.A.","year":"2010","unstructured":"David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Cancer Biol Ther, Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies., 2010, 9, 678-684,","journal-title":"Cancer Biol Ther"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.lfs.2010.12.017","volume":"88","author":"Wedel S.","year":"2011","unstructured":"Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Life sciences, Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001., 2011, 88, 418-424,","journal-title":"Life sciences"},{"key":"ref=72","first-page":"2823","volume":"8","author":"Zhang X.","year":"2015","unstructured":"Zhang X, Zhang X, Huang T, Geng J, Liu M, Zheng J. Int J Clin Exp Pathol, Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma., 2015, 8, 2823-2828,","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-17-0074","volume":"16","author":"Tran L.N.","year":"2017","unstructured":"Tran LN, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, Michael MZ, Lower KM, Sykes PJ. Mol Cancer Ther, The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer., 2017, 16, 2689-2700,","journal-title":"Mol Cancer Ther"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"Robinson D.","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G. Cell, Integrative clinical genomics of advanced prostate cancer., 2015, 161, 1215-1228,","journal-title":"Cell"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","volume":"332","author":"Taplin M-E.","year":"1995","unstructured":"Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. N Engl J Med, Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer., 1995, 332, 1393-1398,","journal-title":"N Engl J Med"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"Feldman B.J.","year":"2001","unstructured":"Feldman BJ, Feldman D. Nat Rev Cancer, The development of androgen-independent prostate cancer., 2001, 1, 34-45,","journal-title":"Nat Rev Cancer"},{"key":"ref=77","first-page":"3369","volume":"53","author":"stein R.","year":"1993","unstructured":"stein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. Cancer Res, p53 is mutated in a subset of advanced-stage prostate cancers., 1993, 53, 3369-3373,","journal-title":"Cancer Res"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","volume":"66","author":"Zakikhani M.","year":"2006","unstructured":"Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Cancer Res, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells., 2006, 66, 10269-10273,","journal-title":"Cancer Res"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","volume":"110","author":"Gotlieb W.H.","year":"2008","unstructured":"Gotlieb WH, Saumet J, Beauchamp M-C, Gu J, Lau S, Pollak MN, Bruchim I. Gynecol Oncol, \n                        In vitro metformin anti-neoplastic activity in epithelial ovarian cancer., 2008, 110, 246-250,","journal-title":"Gynecol Oncol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1074\/jbc.M705232200","volume":"283","author":"Okoshi R.","year":"2008","unstructured":"Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A, Kizaki H. J Biol Chem, Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress., 2008, 283, 3979-3987,","journal-title":"J Biol Chem"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tcb.2010.03.004","volume":"20","author":"Feng Z.","year":"2010","unstructured":"Feng Z, Levine AJ. Trends Cell Biol, The regulation of energy metabolism and the IGF-1\/mTOR pathways by the p53 protein., 2010, 20, 427-434,","journal-title":"Trends Cell Biol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tcb.2007.04.004","volume":"17","author":"Bensaad K.","year":"2007","unstructured":"Bensaad K, Vousden KH. Trends Cell Biol, p53: New roles in metabolism., 2007, 17, 286-291,","journal-title":"Trends Cell Biol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/15384101.2016.1151582","volume":"15","author":"Chen L.","year":"2016","unstructured":"Chen L, Ahmad N, Liu X. Cell Cycle, Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer., 2016, 15, 840-849,","journal-title":"Cell Cycle"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nrc1455","volume":"4","author":"Bode A.M.","year":"2004","unstructured":"Bode AM, Dong Z. Nat Rev Cancer, Post-translational modification of p53 in tumorigenesis., 2004, 4, 793-805,","journal-title":"Nat Rev Cancer"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0092-8674(00)80521-8","volume":"90","author":"Gu W.","year":"1997","unstructured":"Gu W, Roeder RG. Cell, Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain., 1997, 90, 595-606,","journal-title":"Cell"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1158\/0008-5472.CAN-06-4149","volume":"67","author":"Feng Z.","year":"2007","unstructured":"Feng Z, Hu W, De Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ. Cancer Res, The regulation of AMPK \u03b21, TSC2, and PTEN expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways., 2007, 67, 3043-3053,","journal-title":"Cancer Res"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1210\/en.2003-0982","volume":"144","author":"Hardie D.G.","year":"2003","unstructured":"Hardie DG. Endocrinology, Minireview: The AMP-activated protein kinase cascade: the key sensor of cellular energy status., 2003, 144, 5179-5183,","journal-title":"Endocrinology"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40478-015-0184-4","volume":"3","author":"Nicolini C.","year":"2015","unstructured":"Nicolini C, Ahn Y, Michalski B, Rho JM, Fahnestock M. Acta Neuropathol Commun, Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid., 2015, 3, 3-,","journal-title":"Acta Neuropathol Commun"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-011-9386-8","volume":"28","author":"Wedel S.","year":"2011","unstructured":"Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Clin Exp Metastasis, Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells., 2011, 28, 479-491,","journal-title":"Clin Exp Metastasis"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2012.06.019","volume":"690","author":"Chen H.","year":"2012","unstructured":"Chen H, Dzitoyeva S, Manev H. Eur J Pharmacol, Effect of valproic acid on mitochondrial epigenetics., 2012, 690, 51-59,","journal-title":"Eur J Pharmacol"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Li Y.","year":"2013","unstructured":"Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Cancer Res, Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines., 2013, 73, 483-489,","journal-title":"Cancer Res"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"Tran C.","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A. Science, Development of a second-generation antiandrogen for treatment of advanced prostate cancer., 2009, 324, 787-790,","journal-title":"Science"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1158\/0008-5472.CAN-05-4472","volume":"66","author":"Xu Y.","year":"2006","unstructured":"Xu Y, Chen S-Y, Ross KN, Balk SP. Cancer Res, Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins., 2006, 66, 7783-7792,","journal-title":"Cancer Res"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"25904","DOI":"10.1074\/jbc.M203423200","volume":"277","author":"Gaughan L.","year":"2002","unstructured":"Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. J Biol Chem, Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor., 2002, 277, 25904-25913,","journal-title":"J Biol Chem"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","volume":"66","author":"Xia Q.","year":"2006","unstructured":"Xia Q, Sung J, Chowdhury W, Chen C-I, H\u00f6ti N, Shabbeer S, Carducci M, Rodriguez R. Cancer Res, Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo., 2006, 66, 7237-7244,","journal-title":"Cancer Res"},{"key":"ref=96","first-page":"1293","volume":"32","author":"Iacopino F.","year":"2008","unstructured":"Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P, Sica G. Int J Oncol, Valproic acid activity in androgen-sensitive and-insensitive human prostate cancer cells., 2008, 32, 1293-1303,","journal-title":"Int J Oncol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2011.07.015","volume":"311","author":"Chou Y-W.","year":"2011","unstructured":"Chou Y-W, Chaturvedi NK, Ouyang S, Lin F-F, Kaushik D, Wang J, Kim I, Lin M-F. Cancer Lett, Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells., 2011, 311, 177-186,","journal-title":"Cancer Lett"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11626-006-0009-7","volume":"42","author":"Sobel R.E.","year":"2006","unstructured":"Sobel RE, Wang Y, Sadar MD. In Vitro Cell Dev Biol Anim, Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells., 2006, 42, 33-39,","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"ref=99","author":"Kumari S.","year":"","unstructured":"Kumari S, Schlanger S, Wang D, Liu S, Heemers H. , , , 33-OR43-2:\ndefining co-regulator contribution to AR-dependent transcription\nuncovers a novel AR-WDR77-p53-dependent transcriptional code. In Endocrine Society's 98 Annual Meeting and Expo, Endocrine\nSociety: Boston, 2016,"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"Tomlins S.A.","year":"2005","unstructured":"Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Science, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer., 2005, 310, 644-648,","journal-title":"Science"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"Li J.","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R. Science, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer., 1997, 275, 1943-1947,","journal-title":"Science"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","volume":"69","author":"Attard G.","year":"2009","unstructured":"Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A\u2019Hern R, Levink R, Coumans F, Moreira J, Riisnaes R. Cancer Res, Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer., 2009, 69, 2912-2918,","journal-title":"Cancer Res"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1016191913274","volume":"236","author":"Bastola D.R.","year":"2002","unstructured":"Bastola DR, Pahwa GS, Lin M-F, Cheng P-W. Mol Cell Biochem, Downregulation of PTEN\/MMAC\/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli., 2002, 236, 75-81,","journal-title":"Mol Cell Biochem"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1128\/MCB.20.14.5010-5018.2000","volume":"20","author":"Vazquez F.","year":"2000","unstructured":"Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Mol Cell Biol, Phosphorylation of the PTEN tail regulates protein stability and function., 2000, 20, 5010-5018,","journal-title":"Mol Cell Biol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdi182","volume":"16","author":"Hara S.","year":"2005","unstructured":"Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Ann Oncol, Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor., 2005, 16, 928-933,","journal-title":"Ann Oncol"},{"key":"ref=106","first-page":"94","volume":"4","author":"John J.S.","year":"2012","unstructured":"John JS, Powell K, Conley-LaComb MK, Chinni SR. J Cancer Sci Ther, TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression., 2012, 4, 94-,","journal-title":"J Cancer Sci Ther"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2011.35.1916","volume":"29","author":"Rubin M.A.","year":"2011","unstructured":"Rubin MA, Maher CA, Chinnaiyan AM. J Clin Oncol, Common gene rearrangements in prostate cancer., 2011, 29, 3659-3668,","journal-title":"J Clin Oncol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/0008-5472.CAN-11-2079","volume":"72","author":"Friedlander T.W.","year":"2012","unstructured":"Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM. Cancer Res, Common structural and epigenetic changes in the genome of castration-resistant prostate cancer., 2012, 72, 616-625,","journal-title":"Cancer Res"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/aja.2011.145","volume":"14","author":"Rubin M.A.","year":"2012","unstructured":"Rubin MA. Asian J Androl, ETS rearrangements in prostate cancer., 2012, 14, 393-399,","journal-title":"Asian J Androl"},{"key":"ref=110","first-page":"254","volume":"5","author":"Rahim S.","year":"2013","unstructured":"Rahim S, \u00dcren A. Am J Transl Res, Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer., 2013, 5, 254-,","journal-title":"Am J Transl Res"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1593\/neo.07822","volume":"10","author":"Tomlins S.A.","year":"2008","unstructured":"Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB. Neoplasia (New York, NY), Role of the TMPRSS2-ERG gene fusion in prostate cancer., 2008, 10, 177-,","journal-title":"Neoplasia (New York, NY)"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"e55207","DOI":"10.1371\/journal.pone.0055207","volume":"8","author":"Massoner P.","year":"2013","unstructured":"Massoner P, Kugler KG, Unterberger K, Kuner R, Mueller LA, F\u00e4lth M, Sch\u00e4fer G, Seifarth C, Ecker S, Verdorfer I. PLoS One, Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y., 2013, 8, e55207-,","journal-title":"PLoS One"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/ijc.23885","volume":"123","author":"Bj\u00f6rkman M.","year":"2008","unstructured":"Bj\u00f6rkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, Kallioniemi OP. Int J Cancer, Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG\u2010positive prostate cancer., 2008, 123, 2774-2781,","journal-title":"Int J Cancer"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.370","volume":"41","author":"Carver B.S.","year":"2009","unstructured":"Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT. Nat Genet, Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate., 2009, 41, 619-624,","journal-title":"Nat Genet"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6605554","volume":"102","author":"Reid A.","year":"2010","unstructured":"Reid A, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney D. Br J Cancer, Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer., 2010, 102, 678-684,","journal-title":"Br J Cancer"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1053\/j.gastro.2006.03.020","volume":"130","author":"Bergheim I.","year":"2006","unstructured":"Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, Arteel GE. Gastroenterology, Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1., 2006, 130, 2099-2112,","journal-title":"Gastroenterology"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1681\/ASN.2010111196","volume":"22","author":"Van Beneden K.","year":"2011","unstructured":"Van Beneden K, Geers C, Pauwels M, Mannaerts I, Verbeelen D, van Grunsven LA, Van den Branden C. J Am Soc Nephrol, Valproic acid attenuates proteinuria and kidney injury., 2011, 22, 1863-1875,","journal-title":"J Am Soc Nephrol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1593\/neo.08582","volume":"10","author":"El Sheikh S.S.","year":"2008","unstructured":"El Sheikh SS, Romanska HM, Abel P, Domin J, Lalani E-N. Neoplasia, Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer-a pilot study., 2008, 10, 949-953,","journal-title":"Neoplasia"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"Taylor B.S.","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B. Cancer Cell, Integrative genomic profiling of human prostate cancer., 2010, 18, 11-22,","journal-title":"Cancer Cell"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1073\/pnas.95.26.15587","volume":"95","author":"Wu X.","year":"1998","unstructured":"Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. Proc Natl Acad Sci, The PTEN\/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase\/Akt pathway., 1998, 95, 15587-15591,","journal-title":"Proc Natl Acad Sci"},{"key":"ref=121","first-page":"944","volume":"60","author":"Marcelli M.","year":"2000","unstructured":"Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A. Cancer Res, Androgen receptor mutations in prostate cancer., 2000, 60, 944-949,","journal-title":"Cancer Res"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","volume":"52","author":"Currie C.","year":"2009","unstructured":"Currie C, Poole C, Gale E. Diabetologia, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes., 2009, 52, 1766-1777,","journal-title":"Diabetologia"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","volume":"109","author":"Nobes J.P.","year":"2012","unstructured":"Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. BJU Int, A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy., 2012, 109, 1495-1502,","journal-title":"BJU Int"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/nnm.11.61","volume":"7","author":"Monteagudo S.","year":"2012","unstructured":"Monteagudo S, Perez-Martinez FC, Perez-Carrion MD, Guerra J, Merino S, Sanchez-Verdu MP, Cena V. Nanomedicine, Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells., 2012, 7, 493-506,","journal-title":"Nanomedicine"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"e1536","DOI":"10.1038\/cddis.2014.500","volume":"5","author":"Babcook M.A.","year":"2014","unstructured":"Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, Shukla S, Nanavaty RR, Gupta S. Cell Death Dis, Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells., 2014, 5, e1536-,","journal-title":"Cell Death Dis"},{"key":"ref=126","first-page":"471861","volume":"2015","author":"Bilen M.A.","year":"2015","unstructured":"Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM. Case Rep Oncol Med, Maintenance therapy containing metformin and\/or zyflamend for advanced prostate cancer: A case series., 2015, 2015, 471861-,","journal-title":"Case Rep Oncol Med"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/pros.23235","volume":"76","author":"White-Al Habeeb N.M.","year":"2016","unstructured":"White-Al Habeeb NM, Garcia J, Fleshner N, Bapat B. Prostate, Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells., 2016, 76, 1507-1518,","journal-title":"Prostate"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/ijms18020399","volume":"18","author":"Gonnissen A.","year":"2017","unstructured":"Gonnissen A, Isebaert S, McKee CM, Muschel RJ, Haustermans K. Int J Mol Sci, The effect of metformin and GANT61 combinations on the radiosensitivity of prostate cancer cells., 2017, 18, 399-,","journal-title":"Int J Mol Sci"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.juro.2016.10.069","volume":"197","author":"Mayer M.J.","year":"2017","unstructured":"Mayer MJ, Klotz LH, Venkateswaran V. J Urol, The Effect of metformin use during docetaxel chemotherapy on prostate cancer specific and overall survival of diabetic patients with castration resistant prostate cancer., 2017, 197, 1068-1075,","journal-title":"J Urol"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jsbmb.2010.03.004","volume":"121","author":"Gavrilov V.","year":"2010","unstructured":"Gavrilov V, Leibovich Y, Ariad S, Lavrenkov K, Shany S. J Steroid Biochem Mol Biol, A combined pretreatment of 1,25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells., 2010, 121, 391-394,","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1471-2407-11-375","volume":"11","author":"Wedel S.","year":"2011","unstructured":"Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A, Blaheta RA. BMC Cancer, Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the CDK-cyclin axis., 2011, 11, 375-,","journal-title":"BMC Cancer"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/pros.22525","volume":"72","author":"Hudak L.","year":"2012","unstructured":"Hudak L, Tezeeh P, Wedel S, Makarevic J, Juengel E, Tsaur I, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA. Prostate, Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion., 2012, 72, 1719-1735,","journal-title":"Prostate"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.eursup.2009.08.003","volume":"8","author":"Abrahamsson P-A.","year":"2009","unstructured":"Abrahamsson P-A. Eur Urol Suppl, Improving outcomes in prostate cancer: Time to tackle bone disorders., 2009, 8, 821-822,","journal-title":"Eur Urol Suppl"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/CIRCULATIONAHA.107.744490","volume":"117","author":"Xie Z.","year":"2008","unstructured":"Xie Z, Dong Y, Scholz R, Neumann D, Zou M-H. Circulation, Phosphorylation of LKB1 at serine 428 by protein kinase C-\u03b6 is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells., 2008, 117, 952-962,","journal-title":"Circulation"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"Wheaton W.W.","year":"2014","unstructured":"Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS. eLife, Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis., 2014, 3, e02242-,","journal-title":"eLife"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/cddis.2012.13","volume":"3","author":"Shi W.","year":"2012","unstructured":"Shi W, Xiao D, Wang L, Dong L, Yan Z, Shen Z, Chen S, Chen Y, Zhao W. Cell Death Dis, Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy., 2012, 3, e275-,","journal-title":"Cell Death Dis"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"Gwinn D.M.","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. Mol Cell, AMPK phosphorylation of raptor mediates a metabolic checkpoint., 2008, 30, 214-226,","journal-title":"Mol Cell"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-12-1226-T","volume":"12","author":"Cerezo M.","year":"2013","unstructured":"Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C. Mol Cancer Ther, Metformin blocks melanoma invasion and metastasis development in AMPK\/p53-dependent manner., 2013, 12, 1605-1615,","journal-title":"Mol Cancer Ther"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1101\/gad.10.9.1054","volume":"10","author":"Ko L.J.","year":"1996","unstructured":"Ko LJ, Prives C. Genes Dev, p53: Puzzle and paradigm., 1996, 10, 1054-1072,","journal-title":"Genes Dev"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","volume":"18","author":"Jones R.G.","year":"2005","unstructured":"Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. Mol Cell, AMP-activated protein kinase induces a p53-dependent metabolic checkpoint., 2005, 18, 283-293,","journal-title":"Mol Cell"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"Xu W.","year":"2007","unstructured":"Xu W, Parmigiani R, Marks P. Oncogene, Histone deacetylase inhibitors: molecular mechanisms of action., 2007, 26, 5541-5552,","journal-title":"Oncogene"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"Chipuk J.E.","year":"2004","unstructured":"Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Science, Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis., 2004, 303, 1010-1014,","journal-title":"Science"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","volume":"153","author":"Condorelli F.","year":"2008","unstructured":"Condorelli F, Gnemmi I, Vallario A, Genazzani A, Canonico P. Br J Pharmacol, Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells., 2008, 153, 657-668,","journal-title":"Br J Pharmacol"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.282.5387.290","volume":"282","author":"Bennett M.","year":"1998","unstructured":"Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R, Weissberg P. Science, Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis., 1998, 282, 290-293,","journal-title":"Science"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1440-1711.1999.00837.x","volume":"77","author":"Waring P.","year":"1999","unstructured":"Waring P, M\u00fcllbacher A. Immunol Cell Biol, Cell death induced by the Fas\/Fas ligand pathway and its role in pathology., 1999, 77, 312-317,","journal-title":"Immunol Cell Biol"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.188.11.2033","volume":"188","author":"M\u00fcller M.","year":"1998","unstructured":"M\u00fcller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M. J Exp Med, p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs., 1998, 188, 2033-2045,","journal-title":"J Exp Med"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/MCB.15.6.3032","volume":"15","author":"Owen-Schaub L.B.","year":"1995","unstructured":"Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E. Mol Cell Biol, Wild-type human p53 and a temperature-sensitive mutant induce Fas\/APO-1 expression., 1995, 15, 3032-3040,","journal-title":"Mol Cell Biol"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","volume":"267","author":"Nagata S.","year":"1995","unstructured":"Nagata S, Golstein P. Science, The Fas death factor., 1995, 267, 1449-1456,","journal-title":"Science"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"Minucci S.","year":"2006","unstructured":"Minucci S, Pelicci PG. Nat Rev Cancer, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer., 2006, 6, 38-51,","journal-title":"Nat Rev Cancer"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/pros.23000","volume":"75","author":"Wang Y.","year":"2015","unstructured":"Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J. Prostate, Metformin represses androgen\u2010dependent and androgen\u2010independent prostate cancers by targeting androgen receptor., 2015, 75, 1187-1196,","journal-title":"Prostate"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/164020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T01:43:04Z","timestamp":1568943784000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/164020\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":150,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009618666180724111604","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}